Skip to content
MMJ Gazette
  Saturday 21 February 2026
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
  • Home
  • News
  • CBD
  • Cannabis
  • Drugs
  • Marijuana
  • Tobacco
  • Law
Trending
February 21, 2026The Penny Shortage’s Impact on Cannabis Retail Pricing February 20, 2026Shannon O’Brien Pushes to Make Massachusetts the Cannabis Research Capital February 19, 2026Florida CEO Beats State to $15 Wage with Hemp Boom Cash February 18, 2026Chicago Mayor Veto Saves Delta-8 Drinks at United Center February 14, 2026Colorado Cannabis Sales Plunge Again in 2025 February 13, 2026Missouri Cannabis Sales Smash $1.5 Billion Record in 2025 February 12, 2026Oregon Set to Slash THC Limits in Edibles as Child Poisonings Surge February 11, 2026New Mexico Cannabis Firms Lose Big in Border Seizure Fight February 10, 2026Florida Diverts $4M Opioid Cash to Crush Weed Legalization Bid February 7, 2026Canada’s Medical Cannabis Mistake Leaves Patients Stranded
MMJ Gazette
MMJ Gazette
  • About
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Authors
MMJ Gazette
  Cannabis  High Tide Reconsiders Acquisition of German Cannabis Operator Purecan
CannabisMarijuanaNews

High Tide Reconsiders Acquisition of German Cannabis Operator Purecan

Lars BeckersLars Beckers—February 26, 20250
FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

High Tide, a major player in Canada’s cannabis retail industry, is pulling back on its planned acquisition of German medical marijuana operator Purecan GmbH. The Calgary-based company initially set out to acquire a 51% stake in Purecan for €4.8 million ($4.9 million), but after reviewing the details, it’s now reevaluating how—or if—it wants to proceed.

A Tuesday news release confirmed that while High Tide is still considering alternative ways to work with Purecan, there’s no certainty that a deal will happen.

Why High Tide Is Having Second Thoughts

The original deal, announced on January 13, was meant to give High Tide a foothold in Germany’s growing cannabis market. Purecan, a Frankfurt-based importer, already has key assets that made it an attractive target, including:

  • A European wholesale and import license.
  • Warehousing and logistics capabilities.
  • A telemedicine platform to connect with patients.

Despite these advantages, High Tide’s due diligence process led to hesitation. The company has not publicly disclosed specific concerns, but this kind of pause often signals financial, regulatory, or operational risks that weren’t initially apparent.

One thing is clear: High Tide isn’t ready to fully walk away. The company is keeping the door open for a restructured deal while also exploring other options to break into Germany’s cannabis market.

Germany’s Cannabis Market Is Shifting Fast

Germany is already one of the world’s biggest cannabis importers, with nearly half of its supply coming from Canada. Last April, the country made a major shift by removing marijuana from its narcotics list and legalizing limited adult-use sales. This created fresh business opportunities for both local and international cannabis companies.

But political uncertainty could complicate things. Conservative leader Friedrich Merz recently won the German elections, and his party has been vocal about its opposition to cannabis legalization. This could mean new restrictions or even a rollback of recent reforms, making the landscape more unpredictable for companies like High Tide.

What’s Next for High Tide?

High Tide isn’t giving up on Germany. Even if a deal with Purecan falls through, the company has made it clear that it’s actively seeking other ways to enter the market.

For now, its options could include:

  • Partnering with a different German operator to avoid the risks associated with Purecan.
  • Expanding its wholesale business in Europe without relying on a single acquisition.
  • Waiting to see how German cannabis laws evolve before making a long-term commitment.

With Germany’s regulatory environment in flux, High Tide is playing it safe. But if the market stabilizes, expect the company to make another move soon.

FacebookTwitterPinterestLinkedInTumblrRedditVKWhatsAppEmail

Lars Beckers

Lars Beckers is a distinguished senior content writer at MMJ Gazette, bringing a wealth of experience and expertise to the realm of medical marijuana and cannabis-related content. With a deep understanding of the industry and a passion for sharing knowledge, Lars's articles offer readers comprehensive insights and engaging narratives in the dynamic world of cannabis. Known for his meticulous research, clarity of expression, and commitment to delivering high-quality content, Lars brings a seasoned perspective to his work, educating and informing audiences on the latest trends and developments in the field.

Illinois and Maine Weigh Marijuana Consumption Rules for Venues and Events
MediPharm to Sell British Columbia Cannabis Facility to Rubicon for $4.5M
Related posts
  • Related posts
  • More from author
Cannabis

The Penny Shortage’s Impact on Cannabis Retail Pricing

February 21, 20260
Cannabis

Shannon O’Brien Pushes to Make Massachusetts the Cannabis Research Capital

February 20, 20260
Cannabis

Florida CEO Beats State to $15 Wage with Hemp Boom Cash

February 19, 20260
Load more
Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH
PROMOTIONS
RECENT POSTS
  • The Penny Shortage’s Impact on Cannabis Retail Pricing
  • Shannon O’Brien Pushes to Make Massachusetts the Cannabis Research Capital
  • Florida CEO Beats State to $15 Wage with Hemp Boom Cash
  • Chicago Mayor Veto Saves Delta-8 Drinks at United Center
  • Colorado Cannabis Sales Plunge Again in 2025
  • Missouri Cannabis Sales Smash $1.5 Billion Record in 2025
  • Oregon Set to Slash THC Limits in Edibles as Child Poisonings Surge
  • New Mexico Cannabis Firms Lose Big in Border Seizure Fight
  • Florida Diverts $4M Opioid Cash to Crush Weed Legalization Bid
  • Canada’s Medical Cannabis Mistake Leaves Patients Stranded
    © MMJ Gazette. 2024
    • About
    • Contact Us
    • Privacy Policy
    • Terms and Conditions
    • Authors